Gross Margin ImprovementGross margin came in at 46% compared to 23% in the year-ago period, reflecting a successful shift in commercial strategy.
Product AdoptionMultiple studies highlighting OGM utility for analysis of cancer biomarker chromoanagenesis were published, which could drive market adoption.
Revenue GrowthTotal revenue was $7.4M, representing 21.3% YoY growth and beating our projection of $6.8M.